Companies Dominating the Protein Degeneration Therapy Market
- F. Hoffmann-La Roche AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Amgen Inc.
- Baxter International Inc.
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novo Nordisk A/S
- Pfizer, Inc.
- Sanofi SA
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of protein degeneration therapy is estimated at USD 156.34 billion.
The protein degeneration therapy market size was valued at USD 141 billion in 2024 and is likely to cross USD 674.9 billion by 2037, expanding at more than 12.8% CAGR during the forecast period i.e., between 2025-2037. Growing burden of cancer across the globe and growing advancements in protein degenration therapy will drive the market growth.
North America industry is anticipated to hold largest revenue share of 35% by 2037, impelled by rising spending in healthcare in the region.
The major players in the market are Baxter International Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and others.
